A cardiovascular safety signal has overshadowed positive efficacy data for Amgen Inc./UCB SA's first-in-class osteoporosis therapy Evenity (romosozumab) in the 4,000-patient Phase III ARCH study, and is expected to push back its US approval by at least a year and reduce its blockbuster potential.
The setback follows the failure of Merck & Co. Inc.'s odanacatib last year on a stroke risk and leaves...